(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) (Synonyms: Dehydroxymethylepoxyquinomicin) |
| Catalog No.GC32705 |
(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 287194-40-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(-)-DHMEQ is a potent NF-κB inhibitor.
(-)-DHMEQ binds to cysteine 38 of RelA and cysteine 144 of RelB. (-)-DHMEQ at concentrations greater than 25 µM inhibits the LTβ-induced nuclear translocation of FLAG-RelB WT, whereas the inhibitory effect of (-)-DHMEQ on the nuclear translocation of FLAG-RelB (C144S) became weaker at the same concentrations[1].
[1]. Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677. [2]. Kang J, et al. Exposure to a combination of formaldehyde and DINP aggravated asthma-like pathology through oxidative stress and NF-κB activation. Toxicology. 2018 May 14;404-405:49-58.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *